AV-951;Tivozanib;N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea;AV-951(Tivozanib);1-(2-Chloro-4-(6,7-diMethoxyquinolin-4-yloxy)phenyl)-3-(5-Methylisoxazol-3-yl)urea;TIVOZANIB;AV951;KRN951, TIVOZANIB) (STOPPED USE SINCE THE PATENT ISSUE;N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzaMide
Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
